Aim To explore the expression level and clinical significance of miR-328,miR-22 and miR-147 in coronay heart disease （CHD） patients in plasma and peripheral blood mononuclear cells （PBMC） . Methods 100 cases with CHD and healthy volunteers were screened Expression of miR-328,miR-22 and miR-147 in plasma and PBMC in different groups was detected by real-time quantitative PCR. Results Compared with the patients with non-CHD,the plasma expression of miR-328 and miR-22 in patients with CHD significantly increased,and the plasma expression of miR-147 in patients with CHD significantly decreasedCompared with the non-CHD,the expression of miR-328 in PBMC had no significant difference in CHD group,and the expression of miR-22 in PBMC was up-regulated in CHD group,but the expression of miR-147 in PBMC was obviously down-regulated Compared with the patients with non-AMI,the expression of miR-328 and miR-22 in plasma was significantly increased in AMI,but the expression of miR-147 in plasma was obviously decreased in AMI In addition,the miR-328 and miR-147 levels in PBMC in AMI patients were slightly lower,and the miR-22 level was elevated in PBMC in AMI patients. Conclusion Significantly differently expressed miR-328,miR-22 and miR-147 are expected to be new cardiovascular disease markers or gene therapeutic targets in CHD patients.